Evidence review
Tirzepatide Real-World Evidence
Real-world tirzepatide studies use claims databases, electronic health records, and telehealth cohorts rather than randomisation. They capture what happens outside trial conditions — lower adherence, shorter persistence, and smaller average weight loss — but they cannot establish causation and are vulnerable to selection bias, missing data, and loss to follow-up.
Key takeaways
- Real-world cohorts consistently report shorter persistence than trial protocols achieve.
- Average weight reduction in practice is typically smaller than trial means.
- Discontinuation is driven substantially by cost and access, not only tolerability.
- These studies cannot establish causation and carry selection and attrition bias.
- Real-world data on compounded tirzepatide specifically remains sparse and low-quality.
| Data sources | Claims databases, electronic health records, telehealth cohorts |
|---|---|
| Typical finding | Lower persistence and smaller mean weight loss than trials |
| Main biases | Selection, attrition, unmeasured confounding, missing outcomes |
| Causal inference | Not supported by observational design alone |
| Compounded-specific data | Sparse |
Why is real-world weight loss usually lower than trial weight loss?
Three reasons dominate. Trials supply the medication free, which removes the cost barrier that drives much real-world discontinuation. Trials provide structured follow-up and counselling that routine care rarely matches. And trials enrol people who met eligibility criteria and consented to 72 weeks of monitoring — a more persistent group than the general population.
None of this means the trials were wrong. It means trial results describe optimal conditions, and planning for real life should assume something less.
What can observational data legitimately tell us?
It is well suited to describing patterns of use: how long people actually stay on treatment, what proportion refill, which factors predict discontinuation, and what happens in populations trials excluded. It is poorly suited to answering whether the drug caused an outcome, because the people who continue differ systematically from those who stop.
- Loss to follow-up is heavy in telehealth cohorts and rarely random.
- Weights are often self-reported or missing in claims data.
- Publication and sponsorship patterns can skew which cohorts get reported.
- Compounded-product cohorts rarely verify what was actually dispensed.
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
| Series | Wk 0 | Wk 12 | Wk 24 | Wk 40 | Wk 56 | Wk 72 |
|---|---|---|---|---|---|---|
| Tirzepatide 15 mg | 0% | -6.5% | -12.4% | -16.8% | -19.3% | -20.9% |
| Tirzepatide 5 mg | 0% | -5.1% | -9.3% | -12.4% | -14.2% | -15.0% |
| Placebo | 0% | -1.4% | -2.3% | -2.8% | -3.0% | -3.1% |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Cohorts, persistence, outcomes and bias and access, organised around the primary question of tirzepatide real world study. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Cohorts | Covered on this page | Primary evidence |
| Persistence | Covered on this page | Primary evidence |
| Outcomes | Covered on this page | Primary evidence |
| Bias and access | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with the registered protocol and the peer-reviewed publication |
What are the limits of what this page can tell you?
Every page on this site rests on a specific primary trial record, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the registered protocol and the peer-reviewed publication.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This conclusion is held open to the following evidence:
- New primary evidence bearing directly on tirzepatide real world study.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
What do the technical terms on this page mean?
Definitions for the 4 technical terms this page uses, including adherence, compounded, persistence, placebo — in the specific sense used above.
| adherence | The extent to which a person takes a medicine as prescribed. Real-world adherence to incretin therapy is considerably lower than in trials, which is a principal reason real-world weight outcomes are smaller. |
|---|---|
| compounded | Prepared by a pharmacy rather than manufactured under an approved application. Compounded tirzepatide is not FDA approved and has not been evaluated in any randomised trial. |
| persistence | How long a person continues treatment before stopping altogether. Short persistence is the dominant finding of real-world tirzepatide cohorts. |
| placebo | An inactive comparator given so that the effect of the drug can be separated from the effect of being in a trial. Placebo groups in the SURMOUNT trials still lost some weight, which is why the placebo-subtracted difference matters more than the raw figure. |
Frequently asked questions
Do people lose as much weight in the real world?
Typically less than trial averages, largely because of shorter persistence and less structured support.
Why do people stop taking tirzepatide?
Cost and access feature heavily alongside side effects in real-world reports.
Can real-world studies prove the drug works?
No. They describe patterns; randomised trials establish causation.
Is there real-world data on compounded tirzepatide?
Very little of usable quality, and such studies rarely verify what was actually dispensed.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.